GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:BIOVF) » Definitions » Cash Receipts from Securities Related Activities

BIOVF (Swedish Orphan Biovitrum AB) Cash Receipts from Securities Related Activities


View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Swedish Orphan Biovitrum AB Business Description

Industry
Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).